New generics in the period 2007 to 2011 threaten $100 billion of revenues generated in the United States and Europe. The most dramatic change in this period will arise in the period 2010 to 2012 as the patents covering Lipitor expire.
The loss of revenues to generic substitutes is a major influence on the financial performance of ethical R&D companies. Conversely the successful identification and exploitation of the opportunities afforded by patent expirations provides a major growth driver for the pharmaceutical companies who focus their business on the provision of generic therapeutics.
Generic Competition 2007 to 2011: The impact of patent expiries on sales of major drugs is a 50,000 word report that provides the valuable market data and insight that both ethical and generic pharmaceutical companies will find useful in their business.
This unique report will describe in detail which major selling drugs will be affected by patent expiry and the likely financial effect on the producer company. The following information for each drug is provided:
Indication
Manufacturer
Revenues ($m) for 2001-06 (total and US)
% of company’s 2005 revenues
Share of market segment
Key competitors
Patent Status in US, France, Germany, Italy and UK
Patenting activity by generics companies
Generic regulatory filing activity
Pending litigation issues
Share of market segment
Impact of generic substitutes:
Directly on distributor
Indirectly on competitors
On market segment
Distributor(s)
Franchise defence strategies
Key features of this report
Reviews of over 50 major drugs that will come off patent between 2007 and 2011
Listing of generic regulatory filing activity
Solid overview of market for generic drugs over the next four years
Global product sales figures for years 2001-2005 with share by company revenue & market segment
Use this report to:
Forecast the market share that will be lost to generic competition
Understand which global companies are under pressure from generics
Consider the effect of expiry on the patent holder’s competitors
See whether there are any outstanding litigation issues
Learn which generic companies are active in filing
(0 items)
